Expanding our team to develop and commercialize a potential first-in-class drug for patients with CKD and metabolic acidosis


Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density.


Employment Fraud Alert

Please be aware that we are currently receiving numerous reports of fraudulent activity where individuals are posing as Tricida, Inc. recruiters, seeking to engage with job seekers through fraudulent online advertisements, job search sites, and direct email solicitations. These unauthorized individuals are using Tricida’s name and logo in an attempt to solicit up-front fees and obtain personally identifiable information from interested job seekers. Please know that Tricida does not conduct interviews via chat rooms such as Google Hangouts, use apps similar to Signal, charge candidates an advance fee of any kind (e.g., fees for purchasing equipment), nor does it offer positions of employment without undergoing a thorough recruiting process. Please also note that any correspondence with regard to employment would come from an authorized Tricida.com email address such as hr@tricida.com. If you receive unsolicited offers of employment from people claiming to work for Tricida, we recommend that you do not respond to their inquiries, do not open any attachments, do not click on any hyperlinks, and alert Tricida Human Resources at hr@tricida.com.


Job opportunities